Celularity Inc. Forecasted to Post FY2022 Earnings of ($0.61) Per Share (NASDAQ:CELU)

Celularity Inc. (NASDAQ:CELUGet Rating) – Research analysts at Oppenheimer increased their FY2022 earnings estimates for shares of Celularity in a report released on Monday, November 14th. Oppenheimer analyst M. Biegler now anticipates that the company will post earnings per share of ($0.61) for the year, up from their previous forecast of ($0.94). The consensus estimate for Celularity’s current full-year earnings is ($0.93) per share. Oppenheimer also issued estimates for Celularity’s Q4 2022 earnings at ($0.23) EPS, FY2023 earnings at ($0.71) EPS and FY2024 earnings at ($0.67) EPS.

Other equities analysts have also issued reports about the stock. Morgan Stanley decreased their target price on shares of Celularity from $8.00 to $5.00 and set an “equal weight” rating on the stock in a report on Monday, September 12th. Alliance Global Partners initiated coverage on shares of Celularity in a research note on Thursday, August 25th. They issued a “buy” rating and a $15.00 price target on the stock. Finally, Truist Financial reduced their price target on shares of Celularity from $10.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, August 23rd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Celularity Stock Down 4.5 %

CELU stock opened at $1.89 on Wednesday. Celularity has a 12 month low of $1.67 and a 12 month high of $13.19. The firm has a market cap of $261.41 million, a P/E ratio of -11.81 and a beta of 0.29. The company’s 50-day moving average price is $2.28 and its two-hundred day moving average price is $4.03.

Institutional Investors Weigh In On Celularity

Several hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SNC acquired a new stake in Celularity during the 3rd quarter worth approximately $50,000. Alliancebernstein L.P. acquired a new stake in Celularity during the 3rd quarter worth approximately $40,000. State Street Corp boosted its position in Celularity by 197.1% during the 3rd quarter. State Street Corp now owns 609,015 shares of the company’s stock worth $1,407,000 after buying an additional 404,042 shares during the period. Vanguard Group Inc. lifted its position in shares of Celularity by 64.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,985,795 shares of the company’s stock worth $6,897,000 after purchasing an additional 1,172,900 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in shares of Celularity by 632.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 191,134 shares of the company’s stock worth $442,000 after purchasing an additional 165,028 shares during the period. 22.35% of the stock is currently owned by institutional investors and hedge funds.

About Celularity

(Get Rating)

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.

Recommended Stories

Earnings History and Estimates for Celularity (NASDAQ:CELU)

Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.